LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
Nadia Harbeck, H. Zhang, Carlos H. Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L. Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault‐Llorca, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, S.Y. Chui, EA Mittendorf
Topics & Concepts
MedicineAtezolizumabTaxaneInternal medicineClinical endpointAnthracyclineCyclophosphamideBreast cancerOncologyTriple-negative breast cancerChemotherapyPhases of clinical researchPlaceboNeoadjuvant therapyDoxorubicinGastroenterologySurgeryCancerRandomized controlled trialPathologyImmunotherapyPembrolizumabAlternative medicineHER2/EGFR in Cancer ResearchCancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research